Introduction: Dyslipidemia (DL) is a principal risk factor in the pathophysiology of cardiovascular diseases (CVD) and diabetes mellitus (DM). It may correlate with Medoroga, which is a risk factor for diseases like Prameha, Hridroga Jwara, Bhagandara, Vrana, Vataroga, etc. 
INTRODUCTION
Dyslipidemia is a principal risk factor in the pathophysiology of CVD and DM. 1 Across the globe, CVD and DM are the conditions with increase in mortality. 2 It is studied that for every 1% reduction in lipid levels the risk of heart diseases reduces by 2.5%. 3 In India, there has been alarming increase in the prevalence of CVD (sample registration system) and DM. 4 In Ayurveda, DL can be correlated with Medoroga. Faulty diet pattern, lifestyle, and hereditary factors contribute to manifestation of Medoroga. 5 Although not an independent disease entity, it is a risk factor for diseases like Prameha, Jwara, Bhagandara, Vrana, Vataroga, etc. 6 According to Acharya Susruta, Medovaha Srotas dusti leads to Sthaulya (obesity). As mentioned in Ayurvedic classic, due to vitiation of Kapha Dosha, excess Medas gets deposited in the body, especially in the Stana Uras (chest), Udara (abdomen), and Sphik (hip) regions that cause Medoroga. 7 There are so many compound and single drugs that have been described in Ayurvedic classics, including the trial drugs VG and HC for the management of Medoroga and lowering its complications. As VG and HC are commonly used in practice for the management of Medoroga and the pharmacopoeial standards also have been incorporated in Ayurvedic Pharmacopoeia of India (API), both the drugs were selected in this study with the following objectives.
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OBJECTIVES
The primary objective of the study was to assess the clinical efficacy of VG and HC in the management of DL, and the secondary objective was to assess the changes in the quality of life of the subjects of DL.
OUTCOME MEASURES
The primary outcome measure was to assess the changes in lipid profile at 84th day from baseline and secondary outcome measure was to assess the changes in the quality of life of the subjects at 84th day from baseline by using SF-36 Health Survey (RAND) score. It is a widely used standardized questionnaire for measuring self-reported physical and mental health status. This questionnaire consists of 36 questions (items) measuring physical and mental health status in respect of eight health domains, viz., (1) physical functioning, (2) role limitations due to physical health, (3) bodily pain, (4) general health perceptions, (5) vitality (energy/fatigue), (6) social functioning, (7) role limitations due to emotional health, and (8) general mental health (psychological distress/ well-being).
The responses to each of the SF-36 items are scored and totaled according to a standardized scoring protocol. 8 The summed-up scores are expressed as a score on a 0 to 100 scale for each of the eight domains. Higher scores represent better self-perception of health. Among the eight domains, the domains 1, 2, 3, 6, and 7 represent health status as absence of disability, whereas domains 4 and 8 represent health status in terms of both positive and negative health states.
MATERIALS AND METHODS
Study Design and Setting
It was a prospective, multicenter, single-arm study. The trial drugs were administered for 12 weeks with a follow-up at the end of 14th week without any interventions. A total number of 146 individuals (from all three participating centers) of clinically diagnosed cases of DL were enrolled in the study.
Before the enrolment process the written consents of the participants were obtained and all were also informed about the study in detail. The trial drugs were standardized as per the standards and standard operational procedures lay down in the API. The study protocol was approved by the Institutional Ethics Committee of each participating institute and also registered in Clinical Trial Registry of India, CTRI/2012/03/002527.
Inclusion and Exclusion Criteria
Participants of DL belonging to either sex, aged between 18 and 70 years having LDL between 100 and 160 mg/dL and/or serum cholesterol 200 and 250 mg/dL and/ or serum TG 150 to 250 mg/dL and those who were willing and able to participate in the 14 weeks long study were included in the study. Those participants who received any cholesterol-lowering medication within last 8 weeks before the screening, having type III and type IV hypercholesterolemia, poorly controlled hypertension (≥160/100 mm Hg), evidence of malignancy, on prolonged (≥6 weeks) medication with corticosteroids, antidepressants, anticholinergics, immunosuppressants, estrogen replacement therapy, etc., or any other drugs that may to have an influence on the outcome of the study were excluded from the study.
Further, the participants who were suffering from major systemic illness necessitating long-term drug treatment (rheumatoid arthritis, tuberculosis, psycho-neuroendocrinal disorders, etc.), heart diseases, those having uncontrolled DM (blood sugar fasting >250 mg/dL), concurrent serious hepatic disorder [defined as aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT), total bilirubin or alkaline phosphatase (ALP) >2 times upper normal limit], or renal disorders (defined as serum creatinine > 1.2 mg/dL), severe pulmonary dysfunction (uncontrolled asthma and chronic obstructive pulmonary disease), inflammatory bowel disease, pregnant and lactating females, those with history of hypersensitivity to any of the trial drugs were also excluded from the study.
Criteria for Withdrawal
All the participants were free to withdraw from the study at any time on their own. The effort was made to collect the data of such participants by making phone calls.
Trial Interventions
As mentioned in API, part-II, Volume-II, VG 9 was administered orally in a dose of 1 gm (2 tablets of 500 mg each) thrice daily after food with lukewarm water and HC 10 was administered in a dose of 3 gm twice daily for 12 weeks as mentioned in API, part-I, Volume-I. Vyoshadi Guggulu contains Trikatu (Sunthi, Pippali, and Maricha), Triphala (Haritaki, Vibhitaka, and Amalaki), and Trimada (Chitraka, Vidanga, and Musta) in one part each and Guggulu contains nine part in the formulation. Both the drugs were procured in a lot from the selected good manufacturing practices certified company for three centers to avoid the batch variation. The drugs were prepared following the pharmacopoeial standards for each ingredient as well as finished products.
Laboratory Investigations
Laboratory investigations, such as Hb%, total leukocyte count, differential leukocyte count, erythrocyte sedimentation rate (ESR), fetal bovine serum, serum uric acid, serum urea, serum creatinine, aspartate transaminase, alanine transaminase, total protein, serum albumin, serum globulin, serum cholesterol, serum TG, LDL, HDL, VLDL were carried out at baseline and at the end of the study. The investigations were carried out with same methods at three participating centers to avoid the investigation error. The method along with the reagent details is annexed in Supplementary File-1.
STUDY PROCEDURE
All the participants had signed the informed consent form prior to their screening. After their enrolment demographic data, medical history, personal history, family history, and chief complaints were enquired and recorded in the case report form. The Prakriti of the participants was also assessed by a specific questionnaire.
Further, hematological and biochemical investigations were carried out at baseline and end of the intervention period and recorded in the case report form. Participants were followed up on 14th, 28th, 42nd, 56th, 70th, and 84th day (12 weeks) and at the end of 98th day (14 weeks) for clinical assessment. During every follow-up, VG packed in separate containers and HC packed in sachets (3 gm each) were issued to the participants. Drug compliance form was also issued to each participant for filling up to ensure the consumption of medicines and the patients were also instructed to return the empty containers and sachets (Flow Chart 1).
Statistical Analysis
The data were analyzed using Statistical Package for Social Sciences 15.0 version. Clinical symptoms and laboratory parameters were analyzed by repeated measures analysis of variance to elicit the within subjects and between subjects effects at baseline and different time points of follow-up.
RESULTS
Totally, 146 subjects were enrolled in the study. The details of enrolled subjects are depicted in Flow Chart 2. The detail demographic data and other baseline characteristics of analyzed patients are presented in Table 1 . It is revealed that 27.4% of patients belonged to the age group of 45 to 53 years followed by 26.7% in the age group of 54 to 65 years; among them, 79.7% were males and 87.0% patients were married. 95.5% patients were having no addiction, 71.9% patients had normal sleep and 80.8% had regular bowel habits.
Effect of the Drugs on Clinical Signs and Symptoms
Graph 1 shows the effect of VG and HC on clinical symptoms of DL. The mean breathlessness score which was 38.7 ± 29.4 before the treatment reduced to 19.5 ± 17.7 and 17.8 ± 17.85 at the end of the treatment, i.e., 84th day and after follow-up, i.e., 98th day respectively. The mean score of paresthesia which was 26.2 ± 26.15 at baseline reduced to 9.8 ± 15.9 and 9.25 ± 16.1, respectively, at the end of the treatment and after follow-up without intervention. The mean score of confusion which was 21.9 ± 27.5 at baseline reduced to 7.2 ± 14.96 at the end of the treatment period and 6.5 ± 14.1 at the end of follow-up period; and the mean score of fatigue which was 42.1 ± 27.0 before the treatment reduced to 16.6 ± 19.1 at the end of the treatment and 15.75 ± 18.8 at the end of 98th day. The result is statistically significant (p < 0.001). Table 2 shows the effect of trial drugs on lipid profiles. There was a significant reduction (p = 0.003) in the mean serum cholesterol (mg/dL) levels, which was 214.8 at the baseline and reduced to 208.3 at the end of treatment period. There was no significant difference in the parameters, viz., serum TG, serum LDL, and serum VLDL.
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Effect of Trial Drugs on Outcome Measures
Flow Chart 1: Study procedures
Flow Chart 2:
Outflow of the subjects in the study. LOCF: Last observation carried forward Table 3 shows the effect of trial drugs on biochemical parameters, i.e., liver function and renal function and it reveals that all the parameters were within the limits, both at baseline and after the trial interventions. Further, no adverse events/reactions were reported during treatment period. This result established the safety of the trial drugs.
Effect of Drugs on Safety Parameters
Effect of the Trial Drugs on Quality of Life of the Participants
The finding of the study shows that the scores received on eight domains of SF-36 health survey questionnaire, viz., physical functioning, limitation due to physical health, limitation due to emotional problems, energy/fatigue, social well-being, emotional well-being, pain, and general health improved than at the baseline and were statistically significant (p < 0.001) at the end of treatment period, i.e., 84th day and 98th day follow-up period (Graph 2).
DISCUSSION
The purpose of this clinical study was to evaluate the efficacy of VG and HC in DL. The finding of the study shows significant change in correcting DL by reducing serum cholesterol levels and reduction (under normal limits) in systolic blood pressure. The above formulations have also brought in significant amelioration of chief complaints, such as breathlessness, paresthesia, confusion, fatigue, and also have improved quality of life of the participants. In addition, there were no significant changes found in the safety laboratory parameters, i.e., hepatic and renal parameters. Dyslipidemia is a condition with abnormal raised levels of cholesterol and/or fat in the blood. It is an established risk factor too for the coronary artery diseases.
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It can be correlated with the Medoroga in Ayurveda. Medoroga is a Santarpanotha vyadhi caused due to consumption of Sleshmala Ahara, Diwaswapna, and inadequate physical activities, which leads to incomplete processing of Anna Rasa (consumed food); is converted into Ama Dosh. 7 It leads to Medo dhtavagni Mandyata, Medovaha
Srotodushti, and accumulation of Apakwa Medas. Similar to Medoroga, sedentary lifestyle and faulty diet habit are also main causes for DL. In addition to this, it is also known that Kapha Dosha and Meda Dhatu are mutually dependent on each other, so if any causative factor which increases Kapha dosha will result in increase of medas, resulting in DL.
There are several Ayurvedic formulations that have been studied in patients of Medoroga. In a study, a combination of Navaka Guggulu, Sthaulhara Kashaya, prescribed diet and physical exercise produced some significant reduction in chest-abdomen-hip circumference. There was some JRAS improvement in subjective symptoms, but lipid parameters and quality of life were not studied. 6 In a study conducted 13 Purana Guggulu has been described as "Atilekhana" and "Medohara"; it also acts as Agnivardhaka and Srotoshodhaka due to its Teekshna Guna. Being Vishad it eliminates the Snigdha and Picchila Meda and Kapha. 14 Further, some experimental studies on the ingredients of VG and HC have also established hypolipidemic, hypocholesterolemic, and antidyslipidemic action. The hypolipidemic action of Haritaki has been explained through inhibition of cholesterol biosynthesis, increased fecal bile acid excretion, and enhanced plasma cholesterol acyl transferase activity. It has also shown significant effect in reducing total cholesterol (hypocholesterolemic effect), TG, total protein, and elevation of HDL levels. 15, 16 Guggulu has been found to be effective in the treatment of hyperlipidemia. 17 Triphala has also been found to have potent hypolipidemic effect and have shown to be potent in reducing hypercholesteremia and atherosclerosis. 18 24 Ginger has demonstrated decrease in all lipid profile parameters. 25, 26 Also, in a clinical study the results
show that ginger has a significant lipid lowering effect compared with placebo. 27 Therefore, the pharmacological action of VG and HC could be deduced by the rasa panchaka as described above and there are ample properties to elicit Kaphamedohara action of the formulations of VG and HC, which might have contributed to the amelioration of the symptoms of medoroga (DL) and reduction in the serum cholesterol levels. Hence, 12 weeks administration of VG and HC produces antidyslipidemic action. However, long-term administration of VG and HC can throw more light on this phenomenon of elevation of HDL levels.
CONCLUSION
This study, therefore, proves that administration of VG and HC has affirmative action in ameliorating chief complaints of DL (Medodosha), enhancing quality of life of affected person and is safe to use.
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